Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Next Previous
Search
Trial Profile

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 0171 (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Datopotamab deruxtecan (Primary) ; Durvalumab (Primary) ; Monalizumab (Primary) ; Oleclumab (Primary) ; Pemetrexed (Primary) ; Rilvegostomig (Primary) ; Volrustomig (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NeoCOAST 2
  • Sponsors AstraZeneca

    • Most Recent Events

    • 22 Nov 2024 Number of arms changed from 5 to 7. Experimental Arm 6: Rilvegostomig + CTX and Arm 7: Dato-DXd + Rilvegostomig + single agent platinum added to study protocol.
    • 22 Nov 2024 Planned number of patients changed from 490 to 630.
    • 26 Sep 2024 Planned End Date changed from 14 Dec 2029 to 9 May 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top